Clinical Drug Studies

From the advanced search, you can use the IDs below to search within the topic "Clinical Drug Studies" (whose ID is 96), by searching on (96/0) [cluster] (replacing the "96/0" with any cluster id below)

ID	Cluster Name Click to Search	Defining Terms
96/0	Clinical Drug Studies sub-cluster 0	elderly drug drugs patients age adverse therapy treatment prescribing effects
96/1	Clinical Drug Studies sub-cluster 1	nsaids drugs nsaid nonsteroidal inflammatory cox-2 antiinflammatory anti drug gastrointestinal
96/2	Clinical Drug Studies sub-cluster 2	adverse drug reactions drugs reaction reporting effects patients monitoring reports
96/3	Clinical Drug Studies sub-cluster 3	cocaine drug heroin drugs abuse users crack seeking administration addiction
96/4	Clinical Drug Studies sub-cluster 4	alcohol drug drugs abuse alcoholism dependence substance treatment drivers alcoholics
96/5	Clinical Drug Studies sub-cluster 5	arthritis rheumatoid drug antirheumatic ra methotrexate treatment modifying therapy anti
96/6	Clinical Drug Studies sub-cluster 6	abuse drug drugs abuser treatment intravenous abused substance dependence prescription
96/7	Clinical Drug Studies sub-cluster 7	tb drug tuberculosis drugs mdr resistant treatment resistance ivermectin isoniazid
96/8	Clinical Drug Studies sub-cluster 8	liposomes drug liposomal liposome drugs delivery encapsulated encapsulation doxorubicin formulations
96/9	Clinical Drug Studies sub-cluster 9	hypertension antihypertensive drug therapy treatment hypertensive blockers diuretics angiotensin patients
96/10	Clinical Drug Studies sub-cluster 10	cost drug costs drugs effectiveness prescription formulary pharmacy therapy treatment
96/11	Clinical Drug Studies sub-cluster 11	tuberculosis drug drugs resistant resistance mycobacterium isoniazid pulmonary treatment rifampicin
96/12	Clinical Drug Studies sub-cluster 12	addiction drug addicts drugs addict abuse addictive heroin treatment addicted
96/13	Clinical Drug Studies sub-cluster 13	antidepressant drugs antidepressants drug tricyclic depression serotonin effects treatment reuptake
96/14	Clinical Drug Studies sub-cluster 14	asthma migraine drug headache treatment bronchial therapy anti inhaled attacks
96/15	Clinical Drug Studies sub-cluster 15	drug adverse adr events drugs reporting reactions event reports surveillance
96/16	Clinical Drug Studies sub-cluster 16	drug interaction drugs potential adverse pharmacokinetic clinical agents warfarin effects
96/17	Clinical Drug Studies sub-cluster 17	drug resistance mdr multidrug resistant drugs glycoprotein pgp cells efflux
96/18	Clinical Drug Studies sub-cluster 18	drug hiv-1 antiviral resistance drugs antiretroviral viral mutations resistant virus
96/19	Clinical Drug Studies sub-cluster 19	antiepileptic epilepsy drugs seizures drug anticonvulsant seizure aeds phenytoin carbamazepine
96/20	Clinical Drug Studies sub-cluster 20	malaria antimalarial drug falciparum drugs chloroquine plasmodium resistance parasite parasites
96/21	Clinical Drug Studies sub-cluster 21	hiv drug antiretroviral drugs protease resistance inhibitors therapy adherence treatment
96/22	Clinical Drug Studies sub-cluster 22	anti inflammatory drugs steroidal nonsteroidal drug effects agents steroid treatment
96/23	Clinical Drug Studies sub-cluster 23	users drug injecting hiv user drugs intravenous heroin ecstasy treatment
96/24	Clinical Drug Studies sub-cluster 24	anticoagulant drugs heparin anticoagulants warfarin drug antithrombotic oral anticoagulation thrombin
96/25	Clinical Drug Studies sub-cluster 25	drug transport transporters drugs transporter gp efflux glycoprotein resistance uptake
96/26	Clinical Drug Studies sub-cluster 26	tablets drug tablet release formulations dissolution formulation drugs matrix bioavailability
96/27	Clinical Drug Studies sub-cluster 27	antipsychotic drugs schizophrenia drug neuroleptic clozapine antipsychotics atypical dyskinesia tardive
96/28	Clinical Drug Studies sub-cluster 28	prescribing drug drugs prescribed prescription physicians prescriptions patients practice prescribe
96/29	Clinical Drug Studies sub-cluster 29	drugs lipid lowering cholesterol drug statin ldl lipoprotein hmg hdl
96/30	Clinical Drug Studies sub-cluster 30	antifungal amphotericin drug fungal itraconazole candida fluconazole ketoconazole agents albicans
96/31	Clinical Drug Studies sub-cluster 31	ulcer gastric drug peptic ulcers healing duodenal ulceration secretion cimetidine
96/32	Clinical Drug Studies sub-cluster 32	antiarrhythmic drug arrhythmias qt ventricular cardiac atrial amiodarone fibrillation class
96/33	Clinical Drug Studies sub-cluster 33	drug p450 cytochrome cyp drugs cyp3a4 metabolism interactions cyp2d6 enzymes
96/34	Clinical Drug Studies sub-cluster 34	delivery drug systems drugs transdermal applications system release polymers therapeutic
96/35	Clinical Drug Studies sub-cluster 35	microspheres drug release nanoparticles loaded delivery poly polymer size plga
96/36	Clinical Drug Studies sub-cluster 36	brain drug barrier bbb delivery cns blood effects administration transport
96/37	Clinical Drug Studies sub-cluster 37	aspirin drug prostaglandin prostaglandins inhibition inflammatory indomethacin anti effects synthesis
96/38	Clinical Drug Studies sub-cluster 38	prescription drug drugs medicare prescriptions advertising benefit coverage consumer beneficiaries
96/39	Clinical Drug Studies sub-cluster 39	absorption drug drugs intestinal bioavailability oral permeability gastrointestinal intestine administration
96/40	Clinical Drug Studies sub-cluster 40	release drug drugs polymer delivery controlled matrix dissolution released vitro
96/41	Clinical Drug Studies sub-cluster 41	drug drugs inhaled inhalation aerosol lung delivery deposition inhaler respiratory
96/42	Clinical Drug Studies sub-cluster 42	reactions drug drugs hypersensitivity reaction allergic cutaneous allergy induced adverse
96/43	Clinical Drug Studies sub-cluster 43	infusion drug drugs intravenous infusions continuous administration delivery pump pumps
96/44	Clinical Drug Studies sub-cluster 44	drug methadone program programs treatment abuse drugs clients maintenance heroin
96/45	Clinical Drug Studies sub-cluster 45	discovery drug screening drugs development throughput compounds chemistry combinatorial design
96/46	Clinical Drug Studies sub-cluster 46	resistance drug resistant drugs antimicrobial bacteria treatment mechanisms agents multiple
96/47	Clinical Drug Studies sub-cluster 47	psychiatric drug patients disorders treatment patient symptoms psychotropic abuse illness
96/48	Clinical Drug Studies sub-cluster 48	drug drugs pharmacogenetics response genetic pharmacogenetic polymorphisms responses genes variability
96/49	Clinical Drug Studies sub-cluster 49	pharmacokinetic drug drugs pharmacodynamic pharmacodynamics clinical elimination pk parameters therapeutic
96/50	Clinical Drug Studies sub-cluster 50	liver drug drugs hepatic hepatotoxicity injury induced hepatitis disease cholestasis
96/51	Clinical Drug Studies sub-cluster 51	drug information drugs pharmacist pharmacy sources clinical physicians patient data
96/52	Clinical Drug Studies sub-cluster 52	fda drug drugs approval approved food approvals administration regulation rule
96/53	Clinical Drug Studies sub-cluster 53	metabolism drug drugs metabolic metabolizing hepatic enzymes metabolites microsomal studies
96/54	Clinical Drug Studies sub-cluster 54	anticancer drug agents cancer chemotherapy design clinical platinum development tumor
96/55	Clinical Drug Studies sub-cluster 55	drug targets drugs target targeted development discovery therapeutic molecular agents
96/56	Clinical Drug Studies sub-cluster 56	drugs blocking beta adrenergic drug neuromuscular adrenoceptor block propranolol effects
96/57	Clinical Drug Studies sub-cluster 57	psychotropic drug effect hypnotic review utilization prescribing eeg evaluation influence
96/58	Clinical Drug Studies sub-cluster 58	cytotoxic drugs tumour drug tumours cytotoxicity agents vitro treatment chemotherapy
96/59	Clinical Drug Studies sub-cluster 59	dosage drug drugs forms dosages form cyclodextrin cd cyclodextrins oral
96/60	Clinical Drug Studies sub-cluster 60	anesthetic drugs anesthesia drug local anesthetics anaesthetic analgesia propofol sedation
96/61	Clinical Drug Studies sub-cluster 61	drug overdose poisoning drugs death overdoses intoxication poisonings fatal cases
96/62	Clinical Drug Studies sub-cluster 62	skin drug transdermal permeation drugs topical penetration delivery corneum stratum
96/63	Clinical Drug Studies sub-cluster 63	injection drug injecting drugs users idus injections hiv needle syringes
96/64	Clinical Drug Studies sub-cluster 64	oral contraceptives drug drugs contraceptive administration orally contraception agents hypoglycemic
96/65	Clinical Drug Studies sub-cluster 65	drugs obesity drug side bladder urinary effects weight overactive incontinence
96/66	Clinical Drug Studies sub-cluster 66	toxicity drug toxic drugs effects necrolysis toxicities agents epidermal induced
96/67	Clinical Drug Studies sub-cluster 67	trials drug clinical drugs trial phase evaluation efficacy treatment studies
96/68	Clinical Drug Studies sub-cluster 68	dissolution drug solubility drugs solid dispersions bioavailability formulation soluble water
96/69	Clinical Drug Studies sub-cluster 69	drug monitoring therapeutic safety drugs pharmacoepidemiology tdm therapeutics laboratory efficacy
96/70	Clinical Drug Studies sub-cluster 70	drugs immunosuppressive pharmacology drug pharmacological clinical pharmacologic agents symposium immunosuppression
96/71	Clinical Drug Studies sub-cluster 71	combination drug combinations drugs combined therapy treatment synergistic effects agents
96/72	Clinical Drug Studies sub-cluster 72	iron drug oxygen free radical radicals chelators superoxide sperm chelation
96/73	Clinical Drug Studies sub-cluster 73	therapy drug drugs therapies treatment patients disease today patient rational
96/74	Clinical Drug Studies sub-cluster 74	drug behavior drugs behavioral effects amphetamine reinforcement conditioned responding stimulus
96/75	Clinical Drug Studies sub-cluster 75	serum drug drugs albumin levels concentrations phenytoin concentration therapeutic patients
96/76	Clinical Drug Studies sub-cluster 76	drug illicit drugs marijuana students youth school adolescent adolescents alcohol
96/77	Clinical Drug Studies sub-cluster 77	drug dependence misuse drugs problems committee misusers problem education dependency
96/78	Clinical Drug Studies sub-cluster 78	placebo drug blind double drugs effects trial patients controlled study
96/79	Clinical Drug Studies sub-cluster 79	action drug actions mechanism mode effects pharmacological effect studies agents
96/80	Clinical Drug Studies sub-cluster 80	drug drugs prices policy price pricing control policies harm national
96/81	Clinical Drug Studies sub-cluster 81	development drug drugs developing biomarkers countries clinical developments pharmaceutical process
96/82	Clinical Drug Studies sub-cluster 82	drug plasma drugs concentration binding tissue protein distribution free unbound
96/83	Clinical Drug Studies sub-cluster 83	drug subjects drugs subjective effects subject placebo volunteers healthy administration
96/84	Clinical Drug Studies sub-cluster 84	drug clearance drugs excretion renal distribution elimination pharmacokinetics dose disposition
96/85	Clinical Drug Studies sub-cluster 85	drug drugs hair urine testing detection screening abuse samples analysis
96/86	Clinical Drug Studies sub-cluster 86	drug drugs industry pharmaceutical products market product marketing pharmaceuticals regulatory
96/87	Clinical Drug Studies sub-cluster 87	mice drug effect induced morphine administration activity treated kg dose
96/88	Clinical Drug Studies sub-cluster 88	drug drugs cell vitro cytotoxicity effect effects human cytotoxic exposure
96/89	Clinical Drug Studies sub-cluster 89	drug induced drugs lupus agranulocytosis thrombocytopenia anemia parkinsonism erythematosus disease
96/90	Clinical Drug Studies sub-cluster 90	drug eruption drugs fixed eruptions allergy antihistaminic antihistamine due lichenoid
96/91	Clinical Drug Studies sub-cluster 91	administration intravenous drug drugs route food administrative intravenously routes oral
96/92	Clinical Drug Studies sub-cluster 92	drugs nervous central drug system acting anticholinergic man centrally effects
96/93	Clinical Drug Studies sub-cluster 93	eluting drug drugs stent restenosis coronary choice thrombosis antibacterial antiplatelet
96/94	Clinical Drug Studies sub-cluster 94	drug treatment antithyroid heart failure disease thyroid hyperthyroidism vasodilator thyrotoxicosis
96/95	Clinical Drug Studies sub-cluster 95	drugs activity drug active vitro activities bactericidal compounds antibacterial antimicrobial
96/96	Clinical Drug Studies sub-cluster 96	drug analgesic dentistry fever narcotic hypotensive anaesthesia withdrawal angina newer
96/97	Clinical Drug Studies sub-cluster 97	drug letter generic doctors companies tranquilizing names company psychoactive doctor
96/98	Clinical Drug Studies sub-cluster 98	drug war editorial dangerous label errors street update hazards antineoplastic
96/99	Clinical Drug Studies sub-cluster 99	drug orphan hallucinogenic driving promotion psychotherapeutic scene psychedelic nonofficial rx